Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Work In Process: 2023-2025

Historic Work In Process for Tonix Pharmaceuticals Holding (TNXP) over the last 1 years, with Sep 2025 value amounting to $1.5 million.

  • Tonix Pharmaceuticals Holding's Work In Process fell 23.91% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 23.91%. This contributed to the annual value of $213,000 for FY2024, which is 91.61% down from last year.
  • Tonix Pharmaceuticals Holding's Work In Process amounted to $1.5 million in Q3 2025, which was up 17.01% from $1.3 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Work In Process high stood at $2.5 million for Q4 2023, and its period low was $213,000 during Q4 2024.
  • Moreover, its 3-year median value for Work In Process was $1.4 million (2025), whereas its average is $1.4 million.
  • Data for Tonix Pharmaceuticals Holding's Work In Process shows a maximum YoY crashed of 91.61% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Work In Process stood at $2.5 million in 2023, then tumbled by 91.61% to $213,000 in 2024, then decreased by 23.91% to $1.5 million in 2025.
  • Its Work In Process stands at $1.5 million for Q3 2025, versus $1.3 million for Q2 2025 and $664,000 for Q1 2025.